Skip to main content
    G

    Geron Corporation (GERN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.03 (-2.60%)

    Market Cap: $622.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Geron Corporation (GERN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Geron (GERN) to earn -$0.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $235.32M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.09.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy360.0%
    Hold120.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 43.7%.

    Fiscal year ending Dec 31, 2026
    -$0.02
    EPS consensus, revenue $235.32M
    Fiscal year ending Dec 31, 2027
    $0.09
    EPS consensus, revenue $338.08M
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.02-$0.02 to -$0.021$235.32M$234.25M to $236.15M5
    Dec 31, 2027$0.09$0.09 to $0.091$338.08M$311.17M to $413.31M5

    Quarterly Estimates

    The EPS consensus rises from $0.00 for the quarter ending Dec 31, 2026 to $0.01 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.00-$0.01 to $0.027$66.75M$62.71M to $69.97M7
    Mar 31, 2027$0.01$0.01 to $0.011$74.49M$68.46M to $85.60M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202701

    Frequently Asked Questions About GERN

    What is the GERN stock forecast?

    Consensus analyst estimates put Geron's EPS at -$0.02 for the fiscal year ending Dec 31, 2026, on revenue of $235.32M. The consensus rating from 5 analysts is Buy.

    How do analysts rate GERN stock?

    Of 5 analysts covering Geron, 1 rates it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from GERN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.02, with estimates from -$0.02 to -$0.02 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.09, with estimates from $0.09 to $0.09 from 1 analyst.

    What revenue do analysts expect from Geron next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $235.32M, with estimates from $234.25M to $236.15M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $338.08M, with estimates from $311.17M to $413.31M.

    How many analysts cover GERN?

    5 analysts rate Geron stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.